• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

英国家族性卵巢癌筛查研究 I 期年度筛查的结果强调了严格遵循筛查计划的必要性。

Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule.

机构信息

Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

出版信息

J Clin Oncol. 2013 Jan 1;31(1):49-57. doi: 10.1200/JCO.2011.39.7638. Epub 2012 Dec 3.

DOI:10.1200/JCO.2011.39.7638
PMID:23213100
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3530690/
Abstract

PURPOSE

To establish the performance characteristics of annual transvaginal ultrasound and serum CA125 screening for women at high risk of ovarian/fallopian tube cancer (OC/FTC) and to investigate the impact of delayed screening interval and surgical intervention.

PATIENTS AND METHODS

Between May 6, 2002, and January 5, 2008, 3,563 women at an estimated ≥ 10% lifetime risk of OC/FTC were recruited and screened by 37 centers in the United Kingdom. Participants were observed prospectively by centers, questionnaire, and national cancer registries.

RESULTS

Sensitivity for detection of incident OC/FTC at 1 year after last annual screen was 81.3% (95% CI, 54.3% to 96.0%) if occult cancers were classified as false negatives and 87.5% (95% CI, 61.7% to 98.5%) if they were classified as true positives. Positive and negative predictive values of incident screening were 25.5% (95% CI, 14.3 to 40.0) and 99.9% (95% CI, 99.8 to 100) respectively. Four (30.8%) of 13 incident screen-detected OC/FTCs were stage I or II. Compared with women screened in the year before diagnosis, those not screened in the year before diagnosis were more likely to have ≥ stage IIIc disease (85.7% v 26.1%; P = .009). Screening interval was delayed by a median of 88 days before detection of incident OC/FTC. Median interval from detection screen to surgical intervention was 79 days in prevalent and incident OC/FTC.

CONCLUSION

These results in the high-risk population highlight the need for strict adherence to screening schedule. Screening more frequently than annually with prompt surgical intervention seems to offer a better chance of early-stage detection.

摘要

目的

建立对高风险卵巢/输卵管癌(OC/FTC)女性进行年度经阴道超声和血清 CA125 筛查的性能特征,并研究延迟筛查间隔和手术干预的影响。

方法

2002 年 5 月 6 日至 2008 年 1 月 5 日,英国 37 个中心招募了 3563 名估计终生 OC/FTC 风险≥10%的女性进行筛查。参与者由中心、问卷和国家癌症登记处进行前瞻性观察。

结果

如果将隐匿性癌症归类为假阴性,那么在最后一次年度筛查后 1 年检测到 OC/FTC 的敏感性为 81.3%(95%CI,54.3%至 96.0%);如果归类为真阳性,则为 87.5%(95%CI,61.7%至 98.5%)。偶发性筛查的阳性和阴性预测值分别为 25.5%(95%CI,14.3 至 40.0)和 99.9%(95%CI,99.8 至 100)。4(30.8%)例偶发性筛查发现的 OC/FTC 为 I 期或 II 期。与在诊断前一年筛查的女性相比,那些在诊断前一年未筛查的女性更有可能患有≥IIIc 期疾病(85.7%比 26.1%;P=.009)。在偶发性 OC/FTC 检测前,筛查间隔中位数延迟了 88 天。在已确诊和偶发性 OC/FTC 中,从检出筛查到手术干预的中位间隔时间为 79 天。

结论

这些高危人群的结果强调了严格遵守筛查时间表的必要性。与每年一次的筛查相比,更频繁的筛查并及时进行手术干预似乎能提供更早发现的机会。

相似文献

1
Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule.英国家族性卵巢癌筛查研究 I 期年度筛查的结果强调了严格遵循筛查计划的必要性。
J Clin Oncol. 2013 Jan 1;31(1):49-57. doi: 10.1200/JCO.2011.39.7638. Epub 2012 Dec 3.
2
Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.在英国家族性卵巢癌筛查研究的第二阶段中,被诊断为卵巢癌的女性出现分期转移的证据。
J Clin Oncol. 2017 May 1;35(13):1411-1420. doi: 10.1200/JCO.2016.69.9330. Epub 2017 Feb 27.
3
Screening for familial ovarian cancer: a ray of hope and a light to steer by.家族性卵巢癌筛查:一线希望与指引方向的明灯。
J Clin Oncol. 2013 Jan 1;31(1):8-10. doi: 10.1200/JCO.2012.45.4678. Epub 2012 Dec 3.
4
Inherited mutations in fallopian tube, ovarian and primary peritoneal carcinoma: Changes in diagnoses and mutational frequency over 20 years.遗传性输卵管、卵巢和原发性腹膜癌突变:20 多年来诊断和突变频率的变化。
Gynecol Oncol. 2020 Oct;159(1):214-220. doi: 10.1016/j.ygyno.2020.06.509. Epub 2020 Jul 21.
5
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.输卵管卵巢切除术与携带BRCA1或BRCA2基因突变女性患卵巢癌、输卵管癌和腹膜癌的风险
JAMA. 2006 Jul 12;296(2):185-92. doi: 10.1001/jama.296.2.185.
6
Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial.卵巢癌风险算法(ROCA)对前列腺癌、肺癌、结直肠癌和卵巢癌(PLCO)试验死亡率结果的潜在影响。
Int J Cancer. 2013 May 1;132(9):2127-33. doi: 10.1002/ijc.27909. Epub 2012 Nov 5.
7
Prevention and early detection of ovarian cancer: mission impossible?卵巢癌的预防与早期检测:不可能完成的任务?
Recent Results Cancer Res. 2007;174:91-100. doi: 10.1007/978-3-540-37696-5_9.
8
Biology of epithelial ovarian cancer: implications for screening women at high genetic risk.上皮性卵巢癌的生物学特性:对高遗传风险女性筛查的意义。
J Clin Oncol. 2004 Apr 1;22(7):1315-27. doi: 10.1200/JCO.2004.07.179.
9
Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study.基于超声的家族性卵巢癌筛查诊所的结果:一项10年观察性研究。
Ultrasound Obstet Gynecol. 2003 Apr;21(4):378-85. doi: 10.1002/uog.65.
10
Evaluation of Transvaginal Ultrasound plus CA-125 Measurement and Prophylactic Salpingo-Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort Study.经阴道超声联合CA-125检测及预防性输卵管卵巢切除术在不同卵巢癌风险水平女性中的评估:摩德纳研究组队列研究
Oncology. 2017;93(6):377-386. doi: 10.1159/000479155. Epub 2017 Aug 26.

引用本文的文献

1
Gynaecological cancer surveillance for women with Lynch syndrome: systematic review and cost-effectiveness evaluation.林奇综合征女性的妇科癌症监测:系统评价和成本效益评估。
Health Technol Assess. 2024 Aug;28(41):1-228. doi: 10.3310/VBXX6307.
2
Deciphering the Interplay: Thieno[2,3-]pyridine's Impact on Glycosphingolipid Expression, Cytotoxicity, Apoptosis, and Metabolomics in Ovarian Tumor Cell Lines.解析相互作用:噻吩并[2,3-]吡啶对卵巢肿瘤细胞系中糖脂表达、细胞毒性、细胞凋亡和代谢组学的影响。
Int J Mol Sci. 2024 Jun 25;25(13):6954. doi: 10.3390/ijms25136954.
3
Enigma of Ovarian Cancer - Early detection Challenges and Solutions!卵巢癌之谜——早期检测的挑战与解决方案!
J Midlife Health. 2024 Jan-Mar;15(1):3-4. doi: 10.4103/jmh.jmh_52_24. Epub 2024 Apr 4.
4
Screening and prevention of ovarian cancer.卵巢癌的筛查与预防。
Med J Aust. 2024 Mar 18;220(5):264-274. doi: 10.5694/mja2.52227. Epub 2024 Feb 14.
5
Plasma cell-free DNA methylation analysis for ovarian cancer detection: Analysis of samples from a case-control study and an ovarian cancer screening trial.用于卵巢癌检测的无细胞血浆 DNA 甲基化分析:病例对照研究和卵巢癌筛查试验样本的分析。
Int J Cancer. 2024 Feb 15;154(4):679-691. doi: 10.1002/ijc.34757. Epub 2023 Oct 20.
6
Extracellular Vesicle-Packaged circATP2B4 Mediates M2 Macrophage Polarization via miR-532-3p/SREBF1 Axis to Promote Epithelial Ovarian Cancer Metastasis.细胞外囊泡包裹的 circATP2B4 通过 miR-532-3p/SREBF1 轴介导线粒体 ATP 敏感性钙通道 2B4 环状 RNA 促进 M2 型巨噬细胞极化进而促进卵巢上皮性癌细胞转移
Cancer Immunol Res. 2023 Feb 3;11(2):199-216. doi: 10.1158/2326-6066.CIR-22-0410.
7
Advances on Prevention and Screening of Gynecologic Tumors: Are We Stepping Forward?妇科肿瘤的预防与筛查进展:我们在前进吗?
Healthcare (Basel). 2022 Aug 24;10(9):1605. doi: 10.3390/healthcare10091605.
8
Screening and risk reducing surgery for endometrial or ovarian cancers in Lynch syndrome: a systematic review.林奇综合征中子宫内膜癌或卵巢癌的筛查和降低风险手术:系统评价。
Int J Gynecol Cancer. 2022 May 3;32(5):646-655. doi: 10.1136/ijgc-2021-003132.
9
A Review of Breast Cancer Risk Factors in Adolescents and Young Adults.青少年和青年乳腺癌风险因素综述。
Cancers (Basel). 2021 Nov 5;13(21):5552. doi: 10.3390/cancers13215552.
10
Ovarian mass-differentiating benign from malignant. Why the International Ovarian Tumour Analysis rules should be implemented in Australasia.卵巢肿块——鉴别良恶性。为何应在澳大拉西亚地区实施国际卵巢肿瘤分析规则。
Australas J Ultrasound Med. 2018 Aug 22;21(3):121-124. doi: 10.1002/ajum.12108. eCollection 2018 Aug.

本文引用的文献

1
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.筛查对卵巢癌死亡率的影响:前列腺癌、肺癌、结直肠癌和卵巢癌(PLCO)癌症筛查随机对照试验。
JAMA. 2011 Jun 8;305(22):2295-303. doi: 10.1001/jama.2011.766.
2
Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.BRCA 携带者和未知突变状态女性行预防性输卵管卵巢切除术的结局。
BJOG. 2011 Jun;118(7):814-24. doi: 10.1111/j.1471-0528.2011.02920.x. Epub 2011 Mar 10.
3
Ovarian cancer linked to Lynch syndrome typically presents as early-onset, non-serous epithelial tumors.卵巢癌与林奇综合征相关,通常表现为早发性、非浆液性上皮性肿瘤。
Gynecol Oncol. 2011 Jun 1;121(3):462-5. doi: 10.1016/j.ygyno.2011.02.010. Epub 2011 Mar 9.
4
Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data.澳大利亚、加拿大、丹麦、挪威、瑞典和英国的癌症生存状况,1995-2007 年(国际癌症基准合作):基于人群的癌症登记数据分析。
Lancet. 2011 Jan 8;377(9760):127-38. doi: 10.1016/S0140-6736(10)62231-3. Epub 2010 Dec 21.
5
The preclinical natural history of serous ovarian cancer: defining the target for early detection.浆液性卵巢癌的临床前自然史:确定早期检测的目标
PLoS Med. 2009 Jul;6(7):e1000114. doi: 10.1371/journal.pmed.1000114. Epub 2009 Jul 28.
6
Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds.MMR 基因突变与卵巢癌患者的生存:林奇综合征家系中的多中心研究。
J Med Genet. 2010 Feb;47(2):99-102. doi: 10.1136/jmg.2009.068130. Epub 2009 Jul 26.
7
Change in stage distribution observed with annual screening for ovarian cancer in BRCA carriers.在携带BRCA基因的人群中,通过每年进行卵巢癌筛查观察到的分期分布变化。
J Med Genet. 2009 Jun;46(6):423-4. doi: 10.1136/jmg.2009.067462.
8
Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).多模式及超声筛查卵巢癌的敏感性和特异性,以及所检测癌症的分期分布:英国卵巢癌筛查协作试验(UKCTOCS)患病率筛查结果
Lancet Oncol. 2009 Apr;10(4):327-40. doi: 10.1016/S1470-2045(09)70026-9. Epub 2009 Mar 11.
9
Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations.林奇综合征患者结外癌症的累积终生发病率:121个已证实存在突变的家族报告
Clin Genet. 2009 Feb;75(2):141-9. doi: 10.1111/j.1399-0004.2008.01125.x.
10
Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.对BRCA1或BRCA2基因突变携带者行降低风险的输卵管卵巢切除术相关风险降低估计值的荟萃分析。
J Natl Cancer Inst. 2009 Jan 21;101(2):80-7. doi: 10.1093/jnci/djn442. Epub 2009 Jan 13.